GIKLY News and Press, Grifols SA Barcelona ADR From 07/05/23

2023-07-05 10:56:31 ET Summary Grifols is a promising buy opportunity thanks to its potential to reduce its net debt/EBITDA ratio. The company's focus on deleveraging is showing results and is supported by higher savings and better margins. The plasma collection is also recovering...

2023-05-09 22:36:06 ET Grifols, S.A. (GRFS) Q1 2023 Earnings Conference Call May 9, 2023 08:30 AM ET Company Participants Nuria Pascual - IR Thomas Glanzmann - Executive Chairman Victor Grifols Deu - Co-CEO Alfredo Arroyo - CFO Conference Call Participa...

2023-03-06 09:07:53 ET Grifols ( NASDAQ: GRFS ) ( OTCPK:GIKLY ) said it entered a research, development and sublicense agreement with Selagine for developing and selling immunoglobulin eye drops for dry eye disease. Under the agreement, Selagine —  ...

The following slide deck was published by Grifols, S.A. in conjunction with their 2022 Q4 earnings call. For further details see: Grifols, S.A. 2022 Q4 - Results - Earnings Call Presentation

Grifols, S.A. (GRFS) Q4 2022 Earnings Conference Call February 28, 2023 08:30 AM ET Company Participants Nuria Pascual - IR Thomas Glanzmann - Executive Chairman Victor Grifols Deu - Co-CEO Alfredo Arroyo - CFO Conference Call Participants Peter Verdult...

We are value investors. In constructing portfolios for our clients, we seek out companies that we believe are trading in the market at significant discounts to their underlying value. These businesses must offer significant profit potential and be run by managers who think and act as owne...

Grifols (NASDAQ:GRFS) unit Araclon Biotech reported results for the first part of a phase 2 trial of its vaccine ABvac40 for Alzheimer's Disease (AD) and data on two studies of its assay ABtest-MS to identify early-stage AD. The company said ABvac40 meets the main objectives on safe...

FBT is a passive biotechnology ETF, which doesn’t pay any dividend. Baring the past one year, FBT’s price return has outperformed the S&P 500. Effective portfolio rebalancing may determine its future growth. For further details see: FBT: A Long Term Hol...

Grifols currently trading at a 30% discount to European specialty pharma. Biotest AG Investment analysis. Biotest R&D not priced in. For further details see: Grifols: Short-Term Turbulence But Long-Term Upside

Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...